NanoCarrier Co. Ltd

Research NanoCarrier Co. Ltd (3NQ) on Bullrun: market cap EUR 46.59M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 46.59M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2026JPY 174.50M-JPY 943.88M-JPY 816.67M87.8%-12.9JPY 4.91BJPY 1.60BJPY 3.57B
FY2025JPY 108.52M-JPY 835.38M-JPY 401.62M72.0%-11.85JPY 1.71BJPY 540.24MJPY 2.74B
FY2024JPY 135.51M-JPY 780.00M-JPY 585.08M81.9%-11.1JPY 2.08BJPY 1.11BJPY 3.42B
FY2023JPY 202.19M-JPY 1.31B-JPY 1.09B78.9%-18.7JPY 2.81BJPY 1.11BJPY 4.25B
FY2022JPY 264.03M-JPY 1.88B-JPY 1.76B84.4%-26.9JPY 3.55BJPY 1.15BJPY 5.57B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-14EUR 46.59Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About NanoCarrier Co. Ltd

Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company's pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is NanoCarrier Co. Ltd's market cap?

NanoCarrier Co. Ltd's market capitalization is EUR 46.59M.

What does NanoCarrier Co. Ltd do?

Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company's pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings, Inc. in December 2025. Nano Holdings, Inc.